Loading...

Geoffrey Wahl

TitleAdjunct Professor
InstitutionUniversity of California San Diego
DepartmentMolecular Biology
Address9500 Gilman Drive #0932
La Jolla CA 92093
Phone858-453-4100
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Combining single cell approaches and a developmental perspective to discover stem cell control circuits and the cellular and molecular bases of cancer heterogeneity
    NIH/NCI R35CA197687Aug 1, 2015 - Jul 31, 2022
    Role: Principal Investigator
    High throughput screen for inhibitors of the mdm2/mdmx interaction
    NIH/NIMH R03MH089489Feb 1, 2010 - Nov 30, 2011
    Role: Principal Investigator
    Mouse Models to Elucidate p53 Regulatory Mechanisms
    NIH/NCI R01CA100845Apr 15, 2003 - Mar 31, 2009
    Role: Principal Investigator
    DECONVOLUTION MICROSCOPE FOR LIVE CELL IMAGING
    NIH/NCRR S10RR013692Feb 16, 1999 - Feb 15, 2000
    Role: Principal Investigator
    DNA REPLICATION, CELL CYCLE CONTROL AND GENOME FLUIDITY
    NIH/NIGMS R01GM051104Aug 1, 1993 - Jul 31, 1998
    Role: Principal Investigator
    Mechanisms of Genetic Instability and Tumor Suppression
    NIH/NCI R01CA061449Jul 1, 1993 - Jul 31, 2011
    Role: Principal Investigator
    MOLECULAR GENETIC ANALYSIS OF MAMMALIAN DNA REPLICATION
    NIH/NCI R01CA048405Aug 1, 1988 - Mar 31, 2005
    Role: Principal Investigator
    DETECTION AND CURING OF AMPLIFIED GENES IN CANCER
    NIH/NCI U01CA048405Aug 1, 1988 - Jul 31, 1995
    Role: Principal Investigator
    FASEB RESEARCH CONF--CELLULAR AND MOLECULAR GENETICS
    NIH/NCI R13CA049116Jul 1, 1988 - Jun 30, 1989
    Role: Principal Investigator
    Salk Institute Cancer Training Grant
    NIH/NCI T32CA009370Sep 1, 1980 - Jun 30, 2022
    Role: Co-Principal Investigator
    DRUG RESISTANCE AND GENE AMPLIFICATION IN EUKARYOTES
    NIH/NIGMS R01GM027754Apr 1, 1980 - Jun 30, 1993
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Dravis C, Chung CY, Lytle NK, Herrera-Valdez J, Luna G, Trejo CL, Reya T, Wahl GM. Epigenetic and Transcriptomic Profiling of Mammary Gland Development and Tumor Models Disclose Regulators of Cell State Plasticity. Cancer Cell. 2018 Sep 10; 34(3):466-482.e6. PMID: 30174241.
      View in: PubMed
    2. Giraddi RR, Chung CY, Heinz RE, Balcioglu O, Novotny M, Trejo CL, Dravis C, Hagos BM, Mehrabad EM, Rodewald LW, Hwang JY, Fan C, Lasken R, Varley KE, Perou CM, Wahl GM, Spike BT. Single-Cell Transcriptomes Distinguish Stem Cell State Changes and Lineage Specification Programs in Early Mammary Gland Development. Cell Rep. 2018 Aug 07; 24(6):1653-1666.e7. PMID: 30089273.
      View in: PubMed
    3. Saison-Ridinger M, DelGiorno KE, Zhang T, Kraus A, French R, Jaquish D, Tsui C, Erikson G, Spike BT, Shokhirev MN, Liddle C, Yu RT, Downes M, Evans RM, Saghatelian A, Lowy AM, Wahl GM. Reprogramming pancreatic stellate cells via p53 activation: A putative target for pancreatic cancer therapy. PLoS One. 2017; 12(12):e0189051. PMID: 29211796.
      View in: PubMed
    4. Trejo CL, Luna G, Dravis C, Spike BT, Wahl GM. Lgr5 is a marker for fetal mammary stem cells, but is not essential for stem cell activity or tumorigenesis. NPJ Breast Cancer. 2017; 3:16. PMID: 28649656.
      View in: PubMed
    5. Wahl GM, Spike BT. Cell state plasticity, stem cells, EMT, and the generation of intra-tumoral heterogeneity. NPJ Breast Cancer. 2017; 3:14. PMID: 28649654.
      View in: PubMed
    6. Turner KM, Deshpande V, Beyter D, Koga T, Rusert J, Lee C, Li B, Arden K, Ren B, Nathanson DA, Kornblum HI, Taylor MD, Kaushal S, Cavenee WK, Wechsler-Reya R, Furnari FB, Vandenberg SR, Rao PN, Wahl GM, Bafna V, Mischel PS. Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. Nature. 2017 03 02; 543(7643):122-125. PMID: 28178237.
      View in: PubMed
    7. Sancho-Martinez I, Nivet E, Xia Y, Hishida T, Aguirre A, Ocampo A, Ma L, Morey R, Krause MN, Zembrzycki A, Ansorge O, Vazquez-Ferrer E, Dubova I, Reddy P, Lam D, Hishida Y, Wu MZ, Esteban CR, O'Leary D, Wahl GM, Verma IM, Laurent LC, Izpisua Belmonte JC. Establishment of human iPSC-based models for the study and targeting of glioma initiating cells. Nat Commun. 2016 Feb 22; 7:10743. PMID: 26899176; PMCID: PMC4764898.
    8. Dravis C, Spike BT, Harrell JC, Johns C, Trejo CL, Southard-Smith EM, Perou CM, Wahl GM. Sox10 Regulates Stem/Progenitor and Mesenchymal Cell States in Mammary Epithelial Cells. Cell Rep. 2015 Sep 29; 12(12):2035-48. PMID: 26365194; PMCID: PMC4591253.
    9. Adams CJ, Yu JS, Mao JH, Jen KY, Costes SV, Wade M, Shoemake J, Aina OH, Del Rosario R, Menchavez PT, Cardiff RD, Wahl GM, Balmain A. The Trp53 delta proline (Trp53?P) mouse exhibits increased genome instability and susceptibility to radiation-induced, but not spontaneous, tumor development. Mol Carcinog. 2016 09; 55(9):1387-96. PMID: 26310697; PMCID: PMC4891300 [Available on 09/01/17].
    10. Rozhok AI, Wahl GM, DeGregori J. A Critical Examination of the "Bad Luck" Explanation of Cancer Risk. Cancer Prev Res (Phila). 2015 Sep; 8(9):762-4. PMID: 26122457; PMCID: PMC4849411.
    11. Pfefferle AD, Spike BT, Wahl GM, Perou CM. Luminal progenitor and fetal mammary stem cell expression features predict breast tumor response to neoadjuvant chemotherapy. Breast Cancer Res Treat. 2015 Jan; 149(2):425-37. PMID: 25575446; PMCID: PMC4308649.
    12. Li YC, Rodewald LW, Hoppmann C, Wong ET, Lebreton S, Safar P, Patek M, Wang L, Wertman KF, Wahl GM. A versatile platform to analyze low-affinity and transient protein-protein interactions in living cells in real time. Cell Rep. 2014 Dec 11; 9(5):1946-1958. PMID: 25464845.
      View in: PubMed
    13. Sherman MH, Yu RT, Engle DD, Ding N, Atkins AR, Tiriac H, Collisson EA, Connor F, Van Dyke T, Kozlov S, Martin P, Tseng TW, Dawson DW, Donahue TR, Masamune A, Shimosegawa T, Apte MV, Wilson JS, Ng B, Lau SL, Gunton JE, Wahl GM, Hunter T, Drebin JA, O'Dwyer PJ, Liddle C, Tuveson DA, Downes M, Evans RM. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell. 2014 Sep 25; 159(1):80-93. PMID: 25259922; PMCID: PMC4177038.
    14. Spike BT, Kelber JA, Booker E, Kalathur M, Rodewald R, Lipianskaya J, La J, He M, Wright T, Klemke R, Wahl GM, Gray PC. CRIPTO/GRP78 signaling maintains fetal and adult mammary stem cells ex vivo. Stem Cell Reports. 2014 Apr 08; 2(4):427-39. PMID: 24749068; PMCID: PMC3986630.
    15. Pfefferle AD, Herschkowitz JI, Usary J, Harrell JC, Spike BT, Adams JR, Torres-Arzayus MI, Brown M, Egan SE, Wahl GM, Rosen JM, Perou CM. Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts. Genome Biol. 2013 Nov 12; 14(11):R125. PMID: 24220145; PMCID: PMC4053990.
    16. He G, Zhang YW, Lee JH, Zeng SX, Wang YV, Luo Z, Dong XC, Viollet B, Wahl GM, Lu H. AMP-activated protein kinase induces p53 by phosphorylating MDMX and inhibiting its activity. Mol Cell Biol. 2014 Jan; 34(2):148-57. PMID: 24190973.
      View in: PubMed
    17. Rasmussen NR, Wright TM, Brooks SA, Hacker KE, Debebe Z, Sendor AB, Walker MP, Major MB, Green J, Wahl GM, Rathmell WK. Receptor tyrosine kinase-like orphan receptor 2 (Ror2) expression creates a poised state of Wnt signaling in renal cancer. J Biol Chem. 2013 Sep 06; 288(36):26301-10. PMID: 23893409; PMCID: PMC3764835.
    18. Makarem M, Spike BT, Dravis C, Kannan N, Wahl GM, Eaves CJ. Stem cells and the developing mammary gland. J Mammary Gland Biol Neoplasia. 2013 Jun; 18(2):209-19. PMID: 23624881; PMCID: PMC4161372.
    19. Green JL, La J, Yum KW, Desai P, Rodewald LW, Zhang X, Leblanc M, Nusse R, Lewis MT, Wahl GM. Paracrine Wnt signaling both promotes and inhibits human breast tumor growth. Proc Natl Acad Sci U S A. 2013 Apr 23; 110(17):6991-6. PMID: 23559372; PMCID: PMC3637696.
    20. Green JL, Bauer M, Yum KW, Li YC, Cox ML, Willert K, Wahl GM. Use of a molecular genetic platform technology to produce human Wnt proteins reveals distinct local and distal signaling abilities. PLoS One. 2013; 8(3):e58395. PMID: 23516471; PMCID: PMC3596392.
    21. Wade M, Li YC, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer. 2013 Feb; 13(2):83-96. PMID: 23303139; PMCID: PMC4161369.
    22. Li YC, Wahl GM. What a difference a phosphate makes: life or death decided by a single amino acid in MDM2. Cancer Cell. 2012 May 15; 21(5):595-6. PMID: 22624708.
      View in: PubMed
    23. Lee JH, Jin Y, He G, Zeng SX, Wang YV, Wahl GM, Lu H. Hypoxia activates tumor suppressor p53 by inducing ATR-Chk1 kinase cascade-mediated phosphorylation and consequent 14-3-3? inactivation of MDMX protein. J Biol Chem. 2012 Jun 15; 287(25):20898-903. PMID: 22556425; PMCID: PMC3375513.
    24. Spike BT, Engle DD, Lin JC, Cheung SK, La J, Wahl GM. A mammary stem cell population identified and characterized in late embryogenesis reveals similarities to human breast cancer. Cell Stem Cell. 2012 Feb 03; 10(2):183-97. PMID: 22305568; PMCID: PMC3277444.
    25. Wang YV, Leblanc M, Fox N, Mao JH, Tinkum KL, Krummel K, Engle D, Piwnica-Worms D, Piwnica-Worms H, Balmain A, Kaushansky K, Wahl GM. Fine-tuning p53 activity through C-terminal modification significantly contributes to HSC homeostasis and mouse radiosensitivity. Genes Dev. 2011 Jul 01; 25(13):1426-38. PMID: 21724834; PMCID: PMC3134085.
    26. Spike BT, Wahl GM. p53, Stem Cells, and Reprogramming: Tumor Suppression beyond Guarding the Genome. Genes Cancer. 2011 Apr; 2(4):404-19. PMID: 21779509; PMCID: PMC3135646.
    27. Mizuno H, Spike BT, Wahl GM, Levine AJ. Inactivation of p53 in breast cancers correlates with stem cell transcriptional signatures. Proc Natl Acad Sci U S A. 2010 Dec 28; 107(52):22745-50. PMID: 21149740; PMCID: PMC3012457.
    28. Bernal F, Wade M, Godes M, Davis TN, Whitehead DG, Kung AL, Wahl GM, Walensky LD. A stapled p53 helix overcomes HDMX-mediated suppression of p53. Cancer Cell. 2010 Nov 16; 18(5):411-22. PMID: 21075307.
      View in: PubMed
    29. Wade M, Wang YV, Wahl GM. The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol. 2010 May; 20(5):299-309. PMID: 20172729; PMCID: PMC2910097.
    30. Wang YV, Wade M, Wahl GM. Guarding the guardian: Mdmx plays important roles in setting p53 basal activity and determining biological responses in vivo. Cell Cycle. 2009 Nov 01; 8(21):3443-4. PMID: 19838055; PMCID: PMC2777705.
    31. Ponnamperuma RM, King KE, Elsir T, Glick AB, Wahl GM, Nister M, Weinberg WC. The transcriptional regulatory function of p53 is essential for suppression of mouse skin carcinogenesis and can be dissociated from effects on TGF-beta-mediated growth regulation. J Pathol. 2009 Oct; 219(2):263-74. PMID: 19718706; PMCID: PMC4208754.
    32. Kawamura T, Suzuki J, Wang YV, Menendez S, Morera LB, Raya A, Wahl GM, Izpisúa Belmonte JC. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature. 2009 Aug 27; 460(7259):1140-4. PMID: 19668186; PMCID: PMC2735889.
    33. Wang YV, Leblanc M, Wade M, Jochemsen AG, Wahl GM. Increased radioresistance and accelerated B cell lymphomas in mice with Mdmx mutations that prevent modifications by DNA-damage-activated kinases. Cancer Cell. 2009 Jul 07; 16(1):33-43. PMID: 19573810; PMCID: PMC2758524.
    34. Wade M, Wahl GM. Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? Mol Cancer Res. 2009 Jan; 7(1):1-11. PMID: 19147532; PMCID: PMC2629357.
    35. Wade M, Rodewald LW, Espinosa JM, Wahl GM. BH3 activation blocks Hdmx suppression of apoptosis and cooperates with Nutlin to induce cell death. Cell Cycle. 2008 Jul 01; 7(13):1973-82. PMID: 18604177; PMCID: PMC2625302.
    36. Wang YV, Wade M, Wong E, Li YC, Rodewald LW, Wahl GM. Quantitative analyses reveal the importance of regulated Hdmx degradation for p53 activation. Proc Natl Acad Sci U S A. 2007 Jul 24; 104(30):12365-70. PMID: 17640893; PMCID: PMC1941475.
    37. Toledo F, Wahl GM. MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Int J Biochem Cell Biol. 2007; 39(7-8):1476-82. PMID: 17499002; PMCID: PMC2043116.
    38. Toledo F, Lee CJ, Krummel KA, Rodewald LW, Liu CW, Wahl GM. Mouse mutants reveal that putative protein interaction sites in the p53 proline-rich domain are dispensable for tumor suppression. Mol Cell Biol. 2007 Feb; 27(4):1425-32. PMID: 17158931; PMCID: PMC1800716.
    39. Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer. 2006 Dec; 6(12):909-23. PMID: 17128209.
      View in: PubMed
    40. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM. Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006 Oct 01; 66(19):9339-44. PMID: 16990346.
      View in: PubMed
    41. Wade M, Wong ET, Tang M, Stommel JM, Wahl GM. Hdmx modulates the outcome of p53 activation in human tumor cells. J Biol Chem. 2006 Nov 03; 281(44):33036-44. PMID: 16905769.
      View in: PubMed
    42. Toledo F, Liu CW, Lee CJ, Wahl GM. RMCE-ASAP: a gene targeting method for ES and somatic cells to accelerate phenotype analyses. Nucleic Acids Res. 2006 Jul 26; 34(13):e92. PMID: 16870721; PMCID: PMC1540739.
    43. Toledo F, Krummel KA, Lee CJ, Liu CW, Rodewald LW, Tang M, Wahl GM. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. Cancer Cell. 2006 Apr; 9(4):273-85. PMID: 16616333.
      View in: PubMed
    44. Tang M, Wahl GM, Nistér M. Explaining the biological activity of transactivation-deficient p53 variants. Nat Genet. 2006 Apr; 38(4):395-6; author reply 396-7. PMID: 16570054.
      View in: PubMed
    45. Wong ET, Kolman JL, Li YC, Mesner LD, Hillen W, Berens C, Wahl GM. Reproducible doxycycline-inducible transgene expression at specific loci generated by Cre-recombinase mediated cassette exchange. Nucleic Acids Res. 2005 Oct 04; 33(17):e147. PMID: 16204450; PMCID: PMC1243804.
    46. Buzina A, Aladjem MI, Kolman JL, Wahl GM, Ellis J. Initiation of DNA replication at the human beta-globin 3' enhancer. Nucleic Acids Res. 2005; 33(14):4412-24. PMID: 16085752; PMCID: PMC1183104.
    47. Krummel KA, Lee CJ, Toledo F, Wahl GM. The C-terminal lysines fine-tune P53 stress responses in a mouse model but are not required for stability control or transactivation. Proc Natl Acad Sci U S A. 2005 Jul 19; 102(29):10188-93. PMID: 16006521; PMCID: PMC1177381.
    48. Nistér M, Tang M, Zhang XQ, Yin C, Beeche M, Hu X, Enblad G, van Dyke T, Wahl GM. p53 must be competent for transcriptional regulation to suppress tumor formation. Oncogene. 2005 May 19; 24(22):3563-73. PMID: 15750633.
      View in: PubMed
    49. Stommel JM, Wahl GM. A new twist in the feedback loop: stress-activated MDM2 destabilization is required for p53 activation. Cell Cycle. 2005 Mar; 4(3):411-7. PMID: 15684615.
      View in: PubMed
    50. Thompson T, Tovar C, Yang H, Carvajal D, Vu BT, Xu Q, Wahl GM, Heimbrook DC, Vassilev LT. Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. J Biol Chem. 2004 Dec 17; 279(51):53015-22. PMID: 15471885.
      View in: PubMed
    51. Yamamoto N, Jiang P, Yang M, Xu M, Yamauchi K, Tsuchiya H, Tomita K, Wahl GM, Moossa AR, Hoffman RM. Cellular dynamics visualized in live cells in vitro and in vivo by differential dual-color nuclear-cytoplasmic fluorescent-protein expression. Cancer Res. 2004 Jun 15; 64(12):4251-6. PMID: 15205338.
      View in: PubMed
    52. Stommel JM, Wahl GM. Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation. EMBO J. 2004 Apr 07; 23(7):1547-56. PMID: 15029243; PMCID: PMC391059.
    53. Sears J, Kolman J, Wahl GM, Aiyar A. Metaphase chromosome tethering is necessary for the DNA synthesis and maintenance of oriP plasmids but is insufficient for transcription activation by Epstein-Barr nuclear antigen 1. J Virol. 2003 Nov; 77(21):11767-80. PMID: 14557661; PMCID: PMC229350.
    54. Tergaonkar V, Pando M, Vafa O, Wahl G, Verma I. p53 stabilization is decreased upon NFkappaB activation: a role for NFkappaB in acquisition of resistance to chemotherapy. Cancer Cell. 2002 Jun; 1(5):493-503. PMID: 12124178.
      View in: PubMed
    55. Li Q, Lee JY, Castillo R, Hixon MS, Pujol C, Doppalapudi VR, Shepard HM, Wahl GM, Lobl TJ, Chan MF. NB2001, a novel antibacterial agent with broad-spectrum activity and enhanced potency against beta-lactamase-producing strains. Antimicrob Agents Chemother. 2002 May; 46(5):1262-8. PMID: 11959554; PMCID: PMC127132.
    56. Vafa O, Wade M, Kern S, Beeche M, Pandita TK, Hampton GM, Wahl GM. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell. 2002 May; 9(5):1031-44. PMID: 12049739.
      View in: PubMed
    57. Neuteboom ST, Karjian PL, Boyer CR, Beryt M, Pegram M, Wahl GM, Shepard HM. Inhibition of cell growth by NB1011 requires high thymidylate synthase levels and correlates with p53, p21, bax, and GADD45 induction. Mol Cancer Ther. 2002 Apr; 1(6):377-84. PMID: 12477050.
      View in: PubMed
    58. Boyer CR, Karjian PL, Wahl GM, Pegram M, Neuteboom ST. Nucleoside transport inhibitors, dipyridamole and p-nitrobenzylthioinosine, selectively potentiate the antitumor activity of NB1011. Anticancer Drugs. 2002 Jan; 13(1):29-36. PMID: 11914638.
      View in: PubMed
    59. Aladjem MI, Rodewald LW, Lin CM, Bowman S, Cimbora DM, Brody LL, Epner EM, Groudine M, Wahl GM. Replication initiation patterns in the beta-globin loci of totipotent and differentiated murine cells: evidence for multiple initiation regions. Mol Cell Biol. 2002 Jan; 22(2):442-52. PMID: 11756541; PMCID: PMC139749.